These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 20367521)

  • 1. Novel therapeutics based on inhibiting the interaction of glycogen phosphorylase and GL-subunit of glycogen-associated protein phosphatase 1: WO2009127723.
    Zhang L; Liu H
    Expert Opin Ther Pat; 2010 Jul; 20(7):969-73. PubMed ID: 20367521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the interaction between protein phosphatase 1 glycogen-targeting subunit and glycogen phosphorylase increases glycogen synthesis in primary rat hepatocytes.
    Zibrova D; Grempler R; Streicher R; Kauschke SG
    Biochem J; 2008 Jun; 412(2):359-66. PubMed ID: 18298402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in glycogen phosphorylase inhibitor design.
    Oikonomakos NG; Somsák L
    Curr Opin Investig Drugs; 2008 Apr; 9(4):379-95. PubMed ID: 18393105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).
    Donnier-Maréchal M; Vidal S
    Expert Opin Ther Pat; 2016; 26(2):199-212. PubMed ID: 26666989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The experimental type 2 diabetes therapy glycogen phosphorylase inhibition can impair aerobic muscle function during prolonged contraction.
    Baker DJ; Greenhaff PL; MacInnes A; Timmons JA
    Diabetes; 2006 Jun; 55(6):1855-61. PubMed ID: 16731853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New hepatic targets for glycaemic control in diabetes.
    Agius L
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):587-605. PubMed ID: 18054737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged inhibition of glycogen phosphorylase in livers of Zucker Diabetic Fatty rats models human glycogen storage diseases.
    Floettmann E; Gregory L; Teague J; Myatt J; Hammond C; Poucher SM; Jones HB
    Toxicol Pathol; 2010 Apr; 38(3):393-401. PubMed ID: 20215584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycogen phosphorylase inhibitors.
    Henke BR; Sparks SM
    Mini Rev Med Chem; 2006 Aug; 6(8):845-57. PubMed ID: 16918491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Newly approved and promising antidiabetic agents.
    Combettes M; Kargar C
    Therapie; 2007; 62(4):293-310. PubMed ID: 17983555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epinephrine control of glycogen metabolism in glycogen-associated protein phosphatase PP1G/R(GL) knockout mice.
    Kim JH; DePaoli-Roach AA
    J Biochem Mol Biol; 2002 May; 35(3):283-90. PubMed ID: 12297011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacy.
    Thomson SA; Banker P; Bickett DM; Boucheron JA; Carter HL; Clancy DC; Cooper JP; Dickerson SH; Garrido DM; Nolte RT; Peat AJ; Sheckler LR; Sparks SM; Tavares FX; Wang L; Wang TY; Weiel JE
    Bioorg Med Chem Lett; 2009 Feb; 19(4):1177-82. PubMed ID: 19138846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups.
    Sparks SM; Banker P; Bickett DM; Carter HL; Clancy DC; Dickerson SH; Dwornik KA; Garrido DM; Golden PL; Nolte RT; Peat AJ; Sheckler LR; Tavares FX; Thomson SA; Wang L; Weiel JE
    Bioorg Med Chem Lett; 2009 Feb; 19(3):976-80. PubMed ID: 19095442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residues.
    Sparks SM; Banker P; Bickett DM; Clancy DC; Dickerson SH; Garrido DM; Golden PL; Peat AJ; Sheckler LR; Tavares FX; Thomson SA; Weiel JE
    Bioorg Med Chem Lett; 2009 Feb; 19(3):981-5. PubMed ID: 19095443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (WO2011057959) indole and indazole derivatives as glycogen synthase activators: a patent evaluation.
    Skaltsounis AL; Gaboriaud-Kolar N
    Expert Opin Ther Pat; 2011 Dec; 21(12):1925-9. PubMed ID: 21988345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes.
    Bharate SB; Nemmani KV; Vishwakarma RA
    Expert Opin Ther Pat; 2009 Feb; 19(2):237-64. PubMed ID: 19441920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benzisoxazole analogs as glycogen synthase activators, a patent evaluation (WO2011057956).
    Uto Y
    Expert Opin Ther Pat; 2012 Jun; 22(6):701-7. PubMed ID: 22519818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel design principle validated: glucopyranosylidene-spiro-oxathiazole as new nanomolar inhibitor of glycogen phosphorylase, potential antidiabetic agent.
    Somsák L; Nagy V; Vidal S; Czifrák K; Berzsényi E; Praly JP
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5680-3. PubMed ID: 18793852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of glycogen phosphorylase in liver glycogen metabolism.
    Agius L
    Mol Aspects Med; 2015 Dec; 46():34-45. PubMed ID: 26519772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucokinase and molecular aspects of liver glycogen metabolism.
    Agius L
    Biochem J; 2008 Aug; 414(1):1-18. PubMed ID: 18651836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.